Table 2 Univariate analysis according to baseline clinical parameters
From: A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
OS, mo* | 95% CI | P | ||
|---|---|---|---|---|
Previous gastrectomy | No | 6.7 | 5.3 to 8.2 | .660 |
Yes | 6.7 | |||
Gender | Male | 7.1 | 5.9 to 8.4 | .464 |
Female | 6.6 | 5.9 to 7.3 | ||
Age | < median | 7.1 | 5.9 to 8.4 | .243 |
≥ median | 6.5 | 5.9 to 7.3 | ||
Response to first-line chemotherapy | No | 6.4 | 5.5 to 7.2 | .432 |
Yes | 7.1 | 5.9 to 8.4 | ||
Treatment-free interval | < median | 6.7 | 5.8 to 7.6 | .863 |
≥ median | 6.8 | 5.4 to 8.1 | ||
Performance status | 0 or 1 | 7.1 | 6.2 to 8.1 | .001 |
≥ 2 | 5.4 | 3.8 to 7.1 | ||
Albumin | < median | 6.5 | 5.2 to 7.5 | .553 |
≥ median | 7.1 | 5.9 to 8.3 | ||
Alkaline phosphatase | < median | 6.5 | 5.7 to 7.4 | .886 |
≥ median | 7.1 | 5.6 to 8.6 | ||
Bilirubin | < median | 6.2 | 5.3 to 7.1 | .766 |
≥ median | 7.1 | 5.9 to 8.4 | ||
Calcium | < median | 7.2 | 6.0 to 8.3 | .210 |
≥ median | 5.9 | 5.1 to 6.8 | ||
Hemoglobin | < median | 5.8 | 5.6 to 6.4 | .004 |
≥ median | 8.1 | 7.1 to 9.1 | ||
No. of involved site(s) | 1 | 6.7 | 5.5 to 8.0 | .225 |
≥ 2 | 6.4 | 5.4 to 7.3 | ||
Liver metastasis | No | 7.4 | 5.2 to 9.6 | .497 |
Yes | 6.6 | 5.8 to 7.5 | ||
Bone metastasis | No | 8.4 | 5.2 to 11.6 | .793 |
Yes | 6.6 | 5.9 to 7.4 | ||
Ascites | No | 7.1 | 6.2 to 8.1 | .038 |
Yes | 4.7 | 3.5 to 5.9 | ||
Bone marrow involvement | No | 6.7 | 5.9 to 7.6 | .555 |
Yes | 5.0 | 2.5 to 7.6 | ||
Weight loss | No | 6.7 | 5.8 to 7.5 | .853 |
Yes | 6.6 | 3.4 to 9.9 |